Literature DB >> 10758659

Behavior and autonomic nervous system function assessed via heart period measures: the case of hyperarousal in boys with fragile X syndrome.

M L Boccia1, J E Roberts.   

Abstract

Physiological responses may inform us about and help us to interpret behavioral responses. For example, hyperarousal may be a source of behavior problems in children with fragile X syndrome (FXS). To evaluate this approach, we examined heart period data in specific contexts in boys with FXS and in normally developing chronological-age-matched boys. Spectral analysis was used to evaluate the parasympathetic and sympathetic nervous systems' contributions to heart period. Boys with FXS had shorter interbeat intervals, lower parasympathetic activity, and similar sympathetic activity. Also, the groups were differentially responsive to experimental challenge. These results have important implications for our understanding of the basic nervous system dysfunction in FXS and for the strategies likely to be effective in terms of pharmacological intervention with these children. These methods can be applied to a variety of contexts and populations, including children who are sensory defensive, socially avoidant, inattentive, or hyperactive.

Entities:  

Mesh:

Year:  2000        PMID: 10758659     DOI: 10.3758/bf03200783

Source DB:  PubMed          Journal:  Behav Res Methods Instrum Comput        ISSN: 0743-3808


  14 in total

Review 1.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

2.  Physiological regulation and social-emotional processing in female carriers of the FMR1 premutation.

Authors:  Molly Winston; Kritika Nayar; Abigail L Hogan; Jamie Barstein; Chelsea La Valle; Kevin Sharp; Elizabeth Berry-Kravis; Molly Losh
Journal:  Physiol Behav       Date:  2019-11-22

3.  Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P.

Authors:  R Lane Coffee; Charles R Tessier; Elvin A Woodruff; Kendal Broadie
Journal:  Dis Model Mech       Date:  2010-05-04       Impact factor: 5.758

4.  Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome.

Authors:  Scott S Hall; Amy A Lightbody; Brigid E McCarthy; Karen J Parker; Allan L Reiss
Journal:  Psychoneuroendocrinology       Date:  2011-08-20       Impact factor: 4.905

Review 5.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 6.  Cardiac autonomic regulation in autism and Fragile X syndrome: a review.

Authors:  Jessica Klusek; Jane E Roberts; Molly Losh
Journal:  Psychol Bull       Date:  2014-11-24       Impact factor: 17.737

7.  Physiological arousal in autism and fragile X syndrome: group comparisons and links with pragmatic language.

Authors:  Jessica Klusek; Gary E Martin; Molly Losh
Journal:  Am J Intellect Dev Disabil       Date:  2013-11

8.  Parasympathetic functions in children with sensory processing disorder.

Authors:  Roseann C Schaaf; Teal Benevides; Erna Imperatore Blanche; Barbara A Brett-Green; Janice P Burke; Ellen S Cohn; Jane Koomar; Shelly J Lane; Lucy Jane Miller; Teresa A May-Benson; Diane Parham; Stacey Reynolds; Sarah A Schoen
Journal:  Front Integr Neurosci       Date:  2010-03-09

9.  Validating the Construct of Coercion in Family Routines: Expanding the Unit of Analysis in Behavioral Assessment with Families of Children with Developmental Disabilities.

Authors:  Joseph M Lucyshyn; Larry K Irvin; E Richard Blumberg; Robelyn Laverty; Robert H Horner; Jeffrey R Sprague
Journal:  Res Pract Persons Severe Disabl       Date:  2004-06

10.  Drosophila fragile X mental retardation protein developmentally regulates activity-dependent axon pruning.

Authors:  Charles R Tessier; Kendal Broadie
Journal:  Development       Date:  2008-03-05       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.